Advanced Enzyme Technologies Reports Strong FY26 Results; Board Recommends ₹1.35 Dividend

Advanced Enzyme Technologies held a Board of Directors meeting on May 09, 2026, approving the audited Annual Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2026, along with fourth quarter results. The board also recommended a final dividend of ₹1.35 per equity share (67.5% on face value of ₹2 each) for FY26, subject to shareholder approval at the ensuing 37th Annual General Meeting. The board decided to defer the declaration of an interim dividend, citing the need to preserve capital flexibility for evaluating potential strategic avenues and corporate actions to maximize long-term shareholder value.

Consolidated Financial Performance

Advanced Enzyme Technologies delivered robust consolidated financial results for FY26. Revenue from operations rose to ₹7,457.57 million from ₹6,369.10 million in the previous year. Net profit for the year improved significantly to ₹1,736.08 million from ₹1,339.74 million. Total comprehensive income stood at ₹2,684.19 million compared to ₹1,527.96 million previously. The following table summarises the key consolidated financial metrics:

Metric: Q4 FY26 (Audited) Q4 FY25 (Audited) FY26 (Audited) FY25 (Audited) Revenue from Operations (₹ mn): 2,033.67 1,671.79 7,457.57 6,369.10 Other Income (₹ mn): 72.28 87.45 348.32 330.41 Total Income (₹ mn): 2,105.95 1,759.24 7,805.89 6,699.51 Total Expenses (₹ mn): 1,509.04 1,324.64 5,594.12 4,825.87 Profit Before Tax (₹ mn): 598.04 434.60 2,325.36 1,873.64 Net Profit (₹ mn): 452.52 267.28 1,736.08 1,339.74 Total Comprehensive Income (₹ mn): 931.85 273.87 2,684.19 1,527.96 Basic EPS (₹): 3.84 2.37 15.08 11.72 Diluted EPS (₹): 3.84 2.37 15.06 11.71

Standalone Financial Performance

On a standalone basis, the company also reported strong growth. Standalone revenue from operations grew to ₹4,527.66 million from ₹3,514.11 million. Net profit for the year rose to ₹1,318.06 million from ₹1,024.20 million. The key standalone financial highlights are presented below:

Metric: Q4 FY26 (Audited) Q4 FY25 (Audited) FY26 (Audited) FY25 (Audited) Revenue from Operations (₹ mn): 1,164.10 872.06 4,527.66 3,514.11 Other Income (₹ mn): 51.63 45.30 633.88 614.90 Total Income (₹ mn): 1,215.73 917.36 5,161.54 4,129.01 Total Expenses (₹ mn): 927.30 762.27 3,546.22 2,923.73 Profit Before Tax (₹ mn): 288.43 155.09 1,576.74 1,205.28 Net Profit (₹ mn): 222.95 110.54 1,318.06 1,024.20 Basic EPS (₹): 1.99 0.99 11.78 9.16 Diluted EPS (₹): 1.99 0.99 11.76 9.15

Balance Sheet Highlights

On a consolidated basis, total assets stood at ₹18,387.61 million as at March 31, 2026, compared to ₹16,213.47 million as at March 31, 2025. Total equity increased to ₹16,831.22 million from ₹14,686.70 million. On a standalone basis, total assets were ₹8,036.36 million versus ₹6,886.31 million, with total equity rising to ₹7,096.23 million from ₹6,293.41 million.

Exceptional Items

The consolidated results include exceptional items for FY26 amounting to a net credit of ₹113.59 million. This comprises a reversal of a provision of ₹159.64 million related to a lawsuit against Advanced Supplementary Technologies Corporation (U.S.A.), following a favourable direction by the United States Court of Appeals, partially offset by an additional foreign exchange impact of ₹1.75 million in Q4 FY26. Additionally, the company recognised an incremental impact of ₹46.30 million (gratuity) and ₹1.51 million (compensated absences) under exceptional items in the consolidated results, arising from the Government of India's notification of four Labour Codes on November 21, 2025. On a standalone basis, an exceptional item of ₹38.58 million was recognised on account of the Labour Code changes.

Board and Corporate Developments

The board approved several key corporate actions at its May 09, 2026 meeting. Mr. Mukund Madhusudan Kabra (DIN: 00148294) has been approved for re-appointment as Whole Time Director for a further term of five years effective April 01, 2027 to March 31, 2032, subject to shareholder approval at the 37th AGM. Mr. Pradip Bhailal Shah (DIN: 01225582) has been appointed as an Additional Director (Independent) effective June 12, 2026, to hold office for five years from June 12, 2026 to June 11, 2031, subject to member approval. The board also approved the reappointment of M S K A & Associates LLP, Chartered Accountants (FRN: 105047W/W101187) as Statutory Auditors for a second term of five consecutive years from the conclusion of the 37th AGM till the conclusion of the 42nd AGM.

Share Capital and ESOP Allotment

The board approved the allotment of 49,350 equity shares of face value ₹2 per share pursuant to the exercise of options under the Advanced Enzyme Technologies Limited – Employees Stock Options Scheme 2022. Consequent to this allotment, the paid-up share capital of the company increased from ₹22,38,53,600 comprising 11,19,26,800 equity shares of ₹2 each to ₹22,39,52,300 comprising 11,19,76,150 equity shares of ₹2 each. The statutory auditors, M S K A & Associates LLP, have issued an unmodified audit opinion on both the standalone and consolidated financial results for FY26.

Advanced Enzyme Technologies Limited has announced a conference call for analysts and investors to discuss its financial results for the quarter and year ended March 31, 2026. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to the stock exchanges on May 05, 2026 by Company Secretary and Head – Legal, Sanjay Basantani.

Conference Call Details

The conference call is scheduled for Tuesday, May 12, 2026, at 09:00 hours IST. The following table summarises the key details of the event:

Parameter: Details Date: Tuesday, May 12, 2026 Time: 09:00 Hours IST Primary Dial-in Numbers: +91 86 3416 8438 / +91 86 4536 6489 Participant PIN (International): 4773312#

Participants are advised to dial in at least 5–10 minutes prior to the scheduled time to ensure timely connection. Access numbers for other countries are available on request, and participants may also pre-register via the provided registration link to avoid wait time.

Management Representation

The company's management team representing Advanced Enzyme Technologies on the call will include:

Mr. Mukund Kabra – Whole-time Director

Mr. Beni Prasad Rauka – Chief Financial Officer

Investor Relations Contact

For further information or RSVP, investors and analysts may reach out to the company's Investor Relations representative:

Contact: Details Name: Ronak Saraf Designation: Investor Relations Email: ir@advancedenzymes.com Phone: +91 86578 64146

The information pertaining to the conference call has also been uploaded on the company's official website. Advanced Enzyme Technologies is headquartered at 5th Floor, 'A' Wing, Sun Magnetica, Louiswadi, Thane (W) – 400 604, and can be reached at +91 22 41703200.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.